Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases
Alimentary Pharmacology & Therapeutics2022Vol. 55(7), pp. 764–777
Citations Over TimeTop 10% of 2022 papers
Hongsheng Yang, Bingyang Li, Qin Guo, Jian Tang, Bo Peng, Ni Ding, Miao Li, Qingfang Yang, Zicheng Huang, Na Diao, Xia Zhu, Jun Deng, Huili Guo, P. Hu, Kang Chao, Xiang Gao
Abstract
Primary responders with CD experienced LOR to ustekinumab at a risk of 21% per person-year and required dose escalation at a risk of 25% per person-year. Fifty-eight per cent of secondary non-responders with CD may benefit from dose escalation. LOR has not been well characterized in patients with UC.
Related Papers
- Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease(2014)
- → Ustekinumab: a novel therapeutic option in Crohn’s disease(2016)10 cited
- → 985 EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY(2024)2 cited
- → EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE(2022)
- → Su1713 IMPACT OF IMMEDIATE OPTIMIZATION OF USTEKINUMAB ON MEDIUM TERM TARGETS IN SEVERE CROHN'S DISEASE: THE MUST STUDY(2023)